Puma Biotechnology (PBYI) Income from Continuing Operations (2010 - 2026)
Puma Biotechnology's (PBYI) quarterly Income from Continuing Operations came in at 3753000.0 in Q1 2026, down 226.19% YoY from 2974000.0 in Q1 2025, and down 122.26% on a QoQ basis from 16862000.0 in Q4 2025.
Puma Biotechnology (PBYI) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 17 years of Income from Continuing Operations data on file, last reported at 3753000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 226.19% year-over-year to 3753000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27808000.0 (up 265.22% YoY) and the FY2025 annual result came in at 34535000.0, up 19834.29% from the prior year.
- Income from Continuing Operations slipped to 3753000.0 in Q1 2026, from 16862000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 20317000.0 in Q3 2024 to a low of 11148000.0 in Q4 2024.
- A 5-year average of 3107823.53 and a median of 2126000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 1710.0% — and 2024, when it slumped 443.68%.
- Tracing PBYI's Income from Continuing Operations over 5 years: stood at 5151000.0 in 2022, then jumped by 341.62% to 12446000.0 in 2023, then plunged by 189.57% to 11148000.0 in 2024, then jumped by 251.26% to 16862000.0 in 2025, then plunged by 122.26% to 3753000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3753000.0 (Q1 2026), 16862000.0 (Q4 2025), and 8844000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 8.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.19 Mn |
| Mar 31, 2026 | -3.75 Mn |
| Dec 31, 2025 | 16.86 Mn |
| Sep 30, 2025 | 8.84 Mn |
| Jun 30, 2025 | 5.86 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | -11.15 Mn |
| Sep 30, 2024 | 20.32 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | 12.45 Mn |
| Sep 30, 2023 | 5.80 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | -5.15 Mn |
| Sep 30, 2022 | -360,000.00 |
| Jun 30, 2022 | 9.37 Mn |
| Mar 31, 2022 | -3.40 Mn |
| Dec 31, 2021 | 4.22 Mn |
| Sep 30, 2021 | -44.67 Mn |